Evidence map›Paper›PMID 37544038›Full record

ReviewDrug and alcohol dependence2023

Methods for handling missing binary data in substance use disorder trials.

Boyu Ren, Stuart R Lipsitz, Roger D Weiss, Garrett M Fitzmaurice

Open access · greenAbstract readReview
In one paragraph

Review in Drug and alcohol dependence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Boyu RenLaboratory for Psychiatric Biostatistics, McLean Hospital, Belmont, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
Stuart R LipsitzDivision of General Medicine, Brigham and Womens Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Roger D WeissDepartment of Psychiatry, Harvard Medical School, Boston, MA, USA; Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA, USA.
Garrett M FitzmauriceLaboratory for Psychiatric Biostatistics, McLean Hospital, Belmont, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, MA, USA. Electronic address: fitzmaur@hsph.harvard.edu.
Harvard University · USBrigham and Women's Hospital · US

Funding

The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
The National Drug Abuse Treatment Clinical Trials Network (U10)U10DA015831 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI CARROLL, KATHLEEN M., WEISS, ROGER D. · 2002 to 2015
$28.8M
Reduction in frequency of drug use as a primary outcome and its relation to changes in health-related and other functional outcomes in stimulant use disorder trialsR33DA042847 · NIDA · MCLEAN HOSPITAL · PI FITZMAURICE, GARRETT M · 2019 to 2021
$1.3M
Reduction in frequency of drug use as a primary outcome and its relation to changes in health-related and other functional outcomes in stimulant use disorder trialsR21DA042847 · NIDA · MCLEAN HOSPITAL · PI FITZMAURICE, GARRETT M · 2016 to 2017
$476k
NIDA NIH HHS R21 DA042847NIDA NIH HHS R33 DA042847NIDA NIH HHS U10 DA015831NIDA NIH HHS UG1 DA015831
6 · The paper itself

Abstract

Missing data are a ubiquitous problem in longitudinal substance use disorder (SUD) clinical trials. In particular, the rates of missingness are often high and study participants often intermittently skip their scheduled outcome assessments, leading to so-called "non-monotone" missing data patterns. Moreover, when the primary outcome is a measure of substance use, study investigators often have strong prior beliefs based on their clinical experience that those participants with missing data are more likely to be using substances at those occasions, i.e., data are missing not at random (MNAR). Although approaches for handling missing data are well-developed when the missing data patterns are monotone, arising primarily from study participants withdrawing from the trial prematurely, fewer methods are available for non-monotone missingness. In this paper we review some conventional, as well as more novel, methods for handling non-monotone missingness in SUD trials when the repeatedly measured outcome variable is binary (e.g., denoting presence/absence of substance use). We compare and contrast the different approaches using data from a longitudinal clinical trial of four psychosocial treatments from the Collaborative Cocaine Treatment Study. We conclude by making some recommendations to the SUD research community concerning how more principled methods for handling missing data can be incorporated in the analysis and reporting of trial results.

Indexed as

Models, StatisticalSubstance-Related DisordersHumansLongitudinal StudiesOutcome Assessment, Health CareResearch DesignDropoutMissing at randomMissing dataMissing not at randomNon-monotone missingnessSensitivity analysis

Identifiers

PMID37544038
PMCPMC10528893
OpenAlexW4384023355

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.